---
title: "Thromboprophylaxis in COVID-19"
---

![thromboprophylaxis-covid](/img/thromboprophylaxis-covid.svg)

:::info
For patients on regular therapeutic anticoagulants who are deteriorating, consider switching to treatment-dose LMWH.
:::

## Thromboprophylaxis doses in COVID-19

### Standard-dose enoxaparin

| Weight | CrCl > 30 | CrCl ⩽ 30 \*|
|---|---|---|
| < 50 kg | 20 mg OD | 20 mg OD |
| 50 - 100 kg | 40 mg OD | 20 mg OD |
| 101 - 150 kg | 40 mg BD | 40 mg OD |
| > 150 kg | 60 mg BD | Seek renal advice |
\* Including dialysis

### Intermediate-dose enoxaparin

| Weight | CrCl > 30 | CrCl ⩽ 30 \*|
|---|---|---|
| < 50 kg | 40 mg OD | 20 mg OD |
| 50 - 100 kg | 40 mg BD | 40 mg OD |
| 101 - 150 kg | 60 mg BD | 60 mg OD |
| > 150 kg | 80 mg BD | Seek renal advice |
\* Including dialysis

### Treatment-dose LMWH

| Weight | CrCl > 30 | CrCl 20 - 30 | CrCl < 20 |
|---|---|---|---|
| < 100 kg | Enoxaparin 1.5 mg/kg OD | Tinzaparin 175 units/kg OD | Tinzaparin 125 units/kg OD \*|
| ≥ 100 kg | Enoxaparin 1 mg/kg BD | Tinzaparin 175 units/kg OD | Tinzaparin 125 units/kg OD \*|
\* Check anti-Xa weekly and liaise with Haemtology

## Extended thromboprophylaxis on inpatient discharge

:::info
There is currently no evidence for routine thromboprophylaxis in patients with mild or moderate COVID-19 who are deemed suitable for discharge from ED.
:::

Consider 14 days of prophylactic anticoagulation from the date of discharge if all of the following are present:

- COVID +ve and still unwell
- No significant bleeding risk factors
- Anticipated reduction in mobility post-discharge
- Any of:
    - Active cancer or cancer treatment
    - Previous VTE and not on regular anticoagulation
    - BMI > 35
    - ITU admission
    - Age > 75

### Anticoagulants for extended thromboprophylaxis in COVID-19

1st-line: Apixaban 2.5 mg PO BD (off-label) or rivaroxaban 10 mg PO OD (off-label)

2nd-line: Standard-dose enoxaparin

:::tip
Consider enoxaparin as 1st-line if:

- Weight < 50 kg or > 140 kg
- CrCl < 15 mL/min
- Drug interactions with apixaban or rivaroxaban
:::

## Paediatrics and maternity

[RCPCH guidance](https://www.rcpch.ac.uk/resources/covid-19-management-children-hospital-and-non-hospitalised)

[RCOG guidance](https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/)